share_log

Head-To-Head Contrast: Akumin (AKU) Vs. Its Competitors

Defense World ·  Oct 1, 2022 01:12

Akumin (NASDAQ:AKU – Get Rating) is one of 46 public companies in the "Medical laboratories" industry, but how does it compare to its rivals? We will compare Akumin to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Insider and Institutional Ownership

25.1% of Akumin shares are owned by institutional investors. Comparatively, 53.5% of shares of all "Medical laboratories" companies are owned by institutional investors. 17.0% of shares of all "Medical laboratories" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Get Akumin alerts:

Analyst Ratings

This is a summary of current recommendations for Akumin and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akumin 2 0 0 0 1.00
Akumin Competitors 136 718 1614 30 2.62
Akumin presently has a consensus target price of $0.63, indicating a potential downside of 63.45%. As a group, "Medical laboratories" companies have a potential upside of 101.03%. Given Akumin's rivals stronger consensus rating and higher possible upside, analysts plainly believe Akumin has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Akumin and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Akumin $421.08 million -$43.29 million -1.60
Akumin Competitors $1.04 billion $57.33 million -0.06

Akumin's rivals have higher revenue and earnings than Akumin. Akumin is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Akumin has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Akumin's rivals have a beta of -1.65, suggesting that their average share price is 265% less volatile than the S&P 500.

Profitability

This table compares Akumin and its rivals' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akumin -14.16% -29.00% -3.87%
Akumin Competitors -1,501.07% -52.65% -22.32%

Summary

Akumin rivals beat Akumin on 9 of the 13 factors compared.

About Akumin

(Get Rating)

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.

Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment